These series report a success rate of approximately 93% to 95% and a 3% risk of major complications when patients are followed up (Table 8). AF in younger patients is usually associated with the accessory pathway and is unlikely to occur after ablation; in contrast, older patients may have recurrence of AF from causes unrelated to the accessory pathway.283,284 Catheter ablation is also effective for treating PJRT (Table 3) by ablating the concealed accessory pathway with a success rate of approximately 90%.283,284 Catheter ablation of an atriofascicular (Mahaim) pathway is successful in preventing reentrant tachycardia in approximately 70% to 100% of patients.285,286 I C-LD Oral beta blockers, diltiazem, or verapamil are indicated for ongoing management of AVRT in patients without pre- excitation on their resting ECG.46,287 See Online Data and 12. Observational studies and clinical experience confirm that beta blockers, diltiazem, and verapamil are effective for preventing recurrent tachycardia in approximately 50% of patients without pre-excitation on their resting ECG (concealed accessory pathway) and are associated with a favorable side effect profile.46,287 IIa B-R Oral flecainide or propafenone is reasonable for ongoing management in patients without structural heart disease or ischemic heart disease who have AVRT and/or pre-excited AF and are not candidates for, or prefer not to undergo, catheter See Online Data and 12. Flecainide and propafenone are beneficial for the treatment of AVRT by directly slowing or blocking conduction over the pathway. These drugs are effective in approximately 85% to 90% of patients, with 30% reporting an absence of tachycardia.45,108,109,112,288 Both drugs have a risk of proarrhythmia resulting in VT that is increased in patients with structural heart disease or ischemic heart disease; in such patients, these drugs are generally avoided. 